[1]鞠晓静.Foxp3+调节性T细胞及程序性死亡受体1在胃癌组织中的表达及其临床病理意义[J].医学信息,2021,34(02):105-107,112.[doi:10.3969/j.issn.1006-1959.2021.02.028]
　JU Xiao-jing.Expression and Clinicopathological Significance of Foxp3+ Regulatory T Cells and Programmed Death Receptor 1 in Gastric Cancer[J].Medical Information,2021,34(02):105-107,112.[doi:10.3969/j.issn.1006-1959.2021.02.028]
点击复制

Foxp3+调节性T细胞及程序性死亡受体1在胃癌组织中的表达及其临床病理意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年02期
页码:
105-107,112
栏目:
论著
出版日期:
2021-01-15

文章信息/Info

Title:
Expression and Clinicopathological Significance of Foxp3+ Regulatory T Cells and Programmed Death Receptor 1 in Gastric Cancer
文章编号:
1006-1959（2021）02-0105-04
作者:
鞠晓静
（天津市武清区中医医院病理科，天津 301700）
Author(s):
JU Xiao-jing
(Department of Pathology,Wuqing District Traditional Chinese Medicine Hospital,Tianjin 301700,China)
关键词:
胃癌; Foxp3+调节性T细胞; 程序性死亡受体1
Keywords:
Gastric cancer; Foxp3+ regulatory T cells; Programmed death receptor 1
分类号:
R735.2；R730.2
DOI:
10.3969/j.issn.1006-1959.2021.02.028
文献标志码:
A
摘要:
目的 观察胃癌组织及癌旁正常组织中Foxp3+调节性T细胞（Foxp3+Tregs）及程序性死亡受体1（PD1）的表达情况，分析两者在胃癌组织中的表达情况与患者临床病理的关系。方法 选取2011年1月~2016年12月我院收治的121例胃癌患者，取其胃癌组织及癌旁正常组织作为标本，采用免疫组化的方法测定患者胃癌组织及癌旁正常组织中Foxp3+Tregs和PD1的表达情况。随访3年，比较Foxp3+Tregs、PD1阳性表达与阴性表达患者的生存情况。结果 胃癌组织中Foxp3+Tregs、PD1阳性表达率分别为61.88%、64.46%，癌旁正常组织中阳性表达率分别为0.83%、1.65%，胃癌组织Foxp3+Tregs、PD1阳性表达率高于癌旁正常组织，差异有统计学意义（P＜0.05）。不同性别、年龄、肿瘤大小及病变位置胃癌组织中Foxp3+Tregs和PD1的表达比较，差异无统计学意义（P＞0.05）；不同肿瘤分化程度、TNM分期及淋巴结转移胃癌组织中Foxp3+Tregs和PD1的表达比较，差异有统计学意义（P＜0.05）；胃癌组织中Foxp3+Tregs与PD1呈正相关（r=0.527，P＜0.05）；随访3年，Foxp3+Tregs与PD1阳性表达患者生存率低于阴性表达患者，差异有统计学意义（P＜0.05）。结论 Foxp3+Tregs与PD1可作为判断患者病情进展及预后的生物学标志，肿瘤分化程度、TNM分期及淋巴结是否转移均会影响其表达情况，Foxp3+Tregs与PD1阳性表达会影响患者的生存率。
Abstract:
Objective To observe the expression of Foxp3+ regulatory T cells (Foxp3+Tregs) and programmed death receptor 1 (PD1) in gastric cancer tissue and normal tissues adjacent to the cancer, and to analyze the expression of the two in gastric cancer tissue and the clinical pathology of patients relationship.Methods A total of 121 gastric cancer patients admitted to our hospital from January 2011 to December 2016 were selected, and their gastric cancer tissues and normal adjacent tissues were taken as specimens.Immunohistochemical method was used to determine the expression of Foxp3+Tregs and PD1 in gastric cancer tissues and adjacent normal tissues. Follow-up for 3 years, compare the survival of Foxp3+Tregs, PD1 positive and negative expression patients.Results The positive expression rates of Foxp3+Tregs and PD1 in gastric cancer tissues were 61.88% and 64.46%, respectively, and the positive expression rates in normal tissues adjacent to cancer were 0.83% and 1.65%, respectively.The positive expression rate of Foxp3+Tregs and PD1 in gastric cancer tissue was higher than that in normal tissues adjacent to cancer,the difference was statistically significant(P<0.05). There was no statistically significant difference in the expression of Foxp3+Tregs and PD1 in gastric cancer tissues of different genders, ages, tumor sizes and lesion locations (P>0.05);The expressions of Foxp3+Tregs and PD1 in gastric cancer tissues with different tumor differentiation, TNM stages and lymph node metastasis were significantly different (P＜0.05); Foxp3+Tregs in gastric cancer tissues were positively correlated with PD1 (r=0.527,P＜0.05);After 3 years of follow-up, the survival rate of Foxp3+Tregs and PD1 positive expression patients was lower than that of negative expression patients,the difference was statistically significant(P<0.05).Conclusion Foxp3+Tregs and PD1 can be used as biological markers for judging the patient’s disease progression and prognosis. The degree of tumor differentiation, TNM stage and lymph node metastasis will all affect their expression. The positive expression of Foxp3+Tregs and PD1 will affect the survival rate of patients.

参考文献/References:

[1]邓波.胃镜下老年上消化道溃疡及胃癌的临床病理特征分析[J].实用癌症杂志,2015(4):509-511. [2]毛丽伟,廖国清,王红梅.胃癌患者不同区域淋巴结和外周血CD4+CD25+Foxp3+调节性T细胞的表达和临床意义[J].免疫学杂志,2016(11):1001-1004. [3]仇俊兰,奉林.胃癌患者外周血CD4+CD25highFOXP3+调节性T细胞的检测及临床意义[J].中国肿瘤临床与康复,2015,22(12):14-17. [4]侯婧瑛,向仍运,陈淑芬,等.Foxp3＋Tregs 和 PD1在胃癌组织中的表达及其临床病理意义[J].中国病理生理杂志,2015,31(10):1744-1749. [5]刘霞.633例胃癌临床病理特征及生存分析[J].临床与病理杂志,2015,35(s1):46-47. [6]王伟,张正坤,张玲,等.高清放大胃镜联合内镜窄带成像技术及靛胭脂染色对早期胃癌诊断的价值[J].中国中西医结合消化杂志,2015,23(9):644-646. [7]王少辉,张家墉,王力.不同清扫方式根治术治疗进展期胃癌的疗效和安全性[J].兰州大学学报:医学版,2019(3):45-48. [8]郑积华,周娟,谢波,等.不同化疗方案治疗老年晚期胃癌患者的疗效和安全性比较[J].实用医学杂志,2014(13):2086-2087. [9]高俊,邱秀娟,王琦三.营养风险筛查对胃癌手术并发症发生率的预测价值[J].中国肿瘤临床,2015(5):271-276. [10]高强,邱双健,樊嘉.CD4+CD25+FOXP3+调节性T细胞在肿瘤免疫逃逸中的作用研究进展[J].中国癌症杂志,2007,17(8):657-662. [11]陆威.CD4+CD25+调节性T细胞、Foxp3、TGF-β1在胃癌中的表达及临床意义的研究[D].安徽医科大学,2013. [12]马可,张喜平.胃癌病人外周血及肿瘤组织调节性T细胞的表达水平及临床意义[J].内蒙古医科大学学报,2017(5):422-425,430. [13]苏月颖,安秀梅,赵华,等.调节性T细胞和CD8+T细胞在恶性黑色素瘤中的表达及其与预后的关系[J].天津医药,2015(9):1026-1030.

相似文献/References:

[1]尹晓华,刘重元,黄 琳,等.胃癌中lncRNAs的研究进展[J].医学信息,2018,31(03):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
　YIN Xiao-hua,LIU Zhong-yuan,HUANG Lin,et al.Research Progress of lncRNAs in Gastric Cancer[J].Medical Information,2018,31(02):10.[doi:10.3969/j.issn.1006-1959.2018.03.004]
[2]芮昆昆,章 波,邰小华,等.基质金属蛋白酶2与蛋白磷酸酶2A的癌性抑制因子在胃癌中的研究进展[J].医学信息,2018,31(03):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
　RUI Kun-kun,ZHANG Bo,TAI Xiao-hua,et al.The Research Progress of Matrix Metalloproteinase 2 and Cancer Inhibitor of Protein Phosphatase 2A in Gastric Cancer[J].Medical Information,2018,31(02):21.[doi:10.3969/j.issn.1006-1959.2018.03.007]
[3]段 巍.1例晚期胃癌化疗并发嗜血细胞综合征患者的护理[J].医学信息,2018,31(10):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
　DUAN Wei.Nursing Care of a Case of Advanced Gastric Carcinoma with Hemophagocytic Syndrome after Chemotherapy[J].Medical Information,2018,31(02):181.[doi:10.3969/j.issn.1006-1959.2018.10.063]
[4]潘理会,李育庄,李春辉.胃癌与高凝血状态关系的研究现状[J].医学信息,2018,31(11):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
　PAN Li-hui,LI Yu-zhuang,LI Chun-hui.Research Status of the Relationship between Gastric Carcinoma and Hypercoagulable State[J].Medical Information,2018,31(02):15.[doi:10.3969/j.issn.1006-1959.2018.11.005]
[5]李虹霞,刘伏山.慢性萎缩性胃炎的中西医治疗[J].医学信息,2022,35(11):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
　LI Hong-Xia,LIU Fu-shan.Treatment of Chronic Atrophic Gastritis with Traditional Chinese and Western Medicine[J].Medical Information,2022,35(02):29.[doi:10.3969/j.issn.1006-1959.2022.11.009]
[6]梁延洋,程艳娜,华柏慧,等.胃癌合并2型糖尿病术后血糖改善的临床观察[J].医学信息,2018,31(17):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
　LIANG Yan-yang,CHENG Yan-na,HUA Bai-hui,et al.Clinical Observation of Postoperative Blood Glucose Improvement in Patients with Gastric Cancer Complicated with Type 2 Diabetes Mellitus[J].Medical Information,2018,31(02):187.[doi:10.3969/j.issn.1006-1959.2018.17.061]
[7]林跃韩,许庆文.腹腔镜uncut Roux-en-Y吻合与传统吻合方式的研究进展[J].医学信息,2018,31(22):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
　LIN Yue-han,XU Qing-wen.Research Progress of Laparoscopic uncut Roux-en-Y Anastomosis and Traditional Anastomosis[J].Medical Information,2018,31(02):31.[doi:10.3969/j.Ⅰssn.1006-1959.2018.22.010]
[8]马玉涛,石文娜,李晓林,等.免疫荧光法检测FSHR与GnRHR在胃癌组织中的分布及其共定位研究[J].医学信息,2018,31(23):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
　MA Yu-tao,SHI Wen-na,LI Xiao-lin,et al.Study on the Distribution and Co-localization of FSHR and GnRHR in Gastric Cancer Tissues by Immunofluorescence Assay[J].Medical Information,2018,31(02):79.[doi:10.3969/j.issn.1006-1959.2018.23.022C]
[9]赵 静.血浆纤维蛋白原和CA724水平在胃癌患者的变化及临床意义[J].医学信息,2018,31(24):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
　ZHAO Jing.Changes and Clinical Significance of Plasma Fibrinogen and CA724 Levels in Patients with Gastric Cancer[J].Medical Information,2018,31(02):82.[doi:10.3969/j.issn.1006-1959.2018.24.021]
[10]万 芳.以贫血为首发症状的消化道恶性肿瘤临床分析[J].医学信息,2018,31(24):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]
　WAN Fang.Clinical Analysis of Digestive Tract Malignancies with Anemia as the First Symptom[J].Medical Information,2018,31(02):175.[doi:10.3969/j.issn.1006-1959.2018.24.054]

更新日期/Last Update: 1900-01-01